Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24599161 | 1.00 | PKM (0.56) | PKMMAPTEPAS1RAB9ASMN1; SMN2 | |
| SCHEMBL263774 | 0.89 | PKM (0.56) | PKMMAPTEPAS1RAB9ASMN1; SMN2 | |
| SCHEMBL1345830 | 0.81 | PKM (0.55) | PKMMAPTEPAS1RAB9ASMN1; SMN2 | |
| SCHEMBL30338496 | 0.79 | PKM (0.61) | PKMMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL21794169 | 0.79 | PKM (0.61) | PKMMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL23677862 | 0.79 | PKM (0.61) | PKMMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL11841091 | 0.77 | PKM (0.59) | PKMMAPTEPAS1RAB9ASMN1; SMN2 | |
| SCHEMBL4355667 | 0.77 | PKM (0.59) | PKMMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5987206 | 0.75 | PKM (0.49) | PKMMAPTEPAS1RAB9ASMN1; SMN2 | |
| SCHEMBL5987213 | 0.75 | PKM (0.49) | PKMMAPTEPAS1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303597-A1 | METAL-LIGAND COMPLEX, CATALYST COMPOSITION FOR PREPARING ETHYLENE-BASED POLYMER CONTAINING THE SAME, AND PREPARATION METHOD OF ETHYLENE -BASED POLYMER USING THE SAME | SABIC SK NEXLENE COMPANY PTE. LTD. (SG) | 2023-09-28 | — | — | US | disclosed |
| EP-4185593-A1 | METAL-LIGAND COMPLEX, CATALYST COMPOSITION FOR PREPARING ETHYLENE-BASED POLYMER CONTAINING THE SAME, AND PREPARATION METHOD OF ETHYLENE-BASED POLYMER USING THE SAME | SABIC SK Nexlene Company Pte. Ltd. (SG) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022144650-A1 | METAL-LIGAND COMPLEX, CATALYST COMPOSITION FOR PREPARING ETHYLENE-BASED POLYMER CONTAINING THE SAME, AND PREPARATION METHOD OF ETHYLENE-BASED POLYMER USING THE SAME | SABIC SK NEXLENE COMPANY PTE. LTD. (SG) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303597-A1 | METAL-LIGAND COMPLEX, CATALYST COMPOSITION FOR PREPARING ETHYLENE-BASED POLYMER CONTAINING THE SAME, AND PREPARATION METHOD OF ETHYLENE -BASED POLYMER USING THE SAME | ETFB, EMC2, ORC3 | PKM 1109/4885MAPT 3132/4885EPAS1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.